Abstract

Research work was single blind placebo-controlled, conducted at General Hospital, Lahore, Pakistan conducted from NOVEMBER 2015 to JANUARY 2016. 75 diagnosed primary hyperlipidemic patients were selected with age range from 20 to 60 years. Diabetes mellitus, cigarette smoking/alcohol addictive patients, peptic ulcer disease, hypothyroidism, kidney dysfunction, any heart disease and liver disease. All patients were divided in three groups, ie;  25 in each group. All participant’s baseline lipid profile data were taken and filed in specifically designed Performa, at start of taking medicine. Twenty five patients of group-I were advised to take 10 grams of Flaxseeds in three divided doses after meal. Twenty five patients of group-II were advised to take Ajwain seeds 10 grams in three divided doses after each meal for two months. Twenty five patients of group-III were provided placebo capsules, (containing grinded rice), taking one capsule after each meal. All participants were advised to take these medicines for eight weeks. Followup period: All participants were called fortnightly for their query and follow up. Their LDL-cholesterol, and HDL-cholesterol was determined at the hospital laboratory. In two months therapy by Flaxseeds decreased LDL-cholesterol 6.2 % and increased HDL-cholesterol 7.7 %. Ajwain reduced LDL-cholesterol 8.9 % and HDL-cholesterol increased 13.1 %. All changes are biostatistically significant with p-value of <0.01. Conclusion: It was concluded from the research that both Flaxseeds and Ajwain are effective in Primary Hyperlipidemia, if used for two months with specific concentrations.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.